Antibody-displaying extracellular vesicles for targeted cancer therapy

Extracellular vesicles (EVs) function as natural delivery vectors and mediators of biological signals across tissues. Here, by leveraging these functionalities, we show that EVs decorated with an antibody-binding moiety can be used as a modular delivery system for targeted cancer therapy.

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

EVs are increasingly being investigated as promising biotherapeutics owing to their potential as a natural delivery vector that can transport macromolecular content and surpass biological barriers to the site of interest. EVs are associated with minimal toxicity and improved drug potency, with enhanced tumour penetrance, and retention in tumour cells.  EVs can be bioengineer to express targeting moieties, which we and others have reported previously. Here, the aim was to develop a versatile system by displaying antibodies. Our hypothesis was that this would be beneficial compared to conventional EV targeting systems as the antibodies here can be interchanged depending on the intended target, thereby offering the potential to utilize Fc-EVs as an off-the-shelf modular drug that can be combined with previously approved therapeutic antibodies.  

In our recent publication in NBME, we performed a screen of 9 Fc-binding domains and 9 EV sorting domains to optimize the antibody display. We show that Fc-EVs can be used to enrich EVs by several 100-folds to a cellular target, such as the therapeutically used targets PD-L1 and HER2, both in vitro and in vivo. We also showcased that EVs displaying PD-L1-Ab have a significantly enriched and sustained accumulation in tumour tissue up to 72 hours after one single intravenous injection. Furthermore, when loaded with chemotherapeutic drugs, EVs displaying PD-L1-Ab resulted in an improved anti-tumoral effect with prolonged survival and decreased tumour progression.

We believe that the Fc-EV technology has great potential as it offers the possibility to combine EV-antibody therapy in which targeting and/or therapeutic antibodies facilitate targeted EV delivery with therapeutic cargo that can generate a synergistic effect. In theory, the technology could be applied to multiple diseases and used in multiple combinations, not only limited to classical antibody but could also include e.g.  Fc-fused proteins, antibody-drug conjugates and bi-specific antibodies. Subsequent studies on the Fc-EV concept will hopefully explore the therapeutic potential further and possibly translate it to clinical use.

Please check out our publication and let us know what you think.   

Conceptual illustration of Fc-EV targeted therapy platform

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Go to the profile of Oscar Wiklander
about 2 months ago

and here is the link:

Follow the Topic

Cancer Therapy
Life Sciences > Biological Sciences > Cancer Biology > Cancer Therapy
Life Sciences > Biological Sciences > Biotechnology > Nanobiotechnology
Cancer Immunotherapy
Life Sciences > Biological Sciences > Cancer Biology > Cancer Therapy > Cancer Immunotherapy
Biomedical Engineering and Bioengineering
Technology and Engineering > Biological and Physical Engineering > Biomedical Engineering and Bioengineering